Checkpoint Inhibitors in Relapsed/Refractory Classical Hodgkin Lymphoma.

Tarekegn, Kidist; Colon Ramos, Ana; Singh, Balraj; Sequeira Gross, Harry G; Gupta, Sachin

Tarekegn, Kidist; Colon Ramos, Ana; Singh, Balraj; Sequeira Gross, Harry G; Gupta, Sachin.

Afiliación

Tarekegn K; Department of Internal Medicine, St. Barnabas Hospital, Bronx, NY 10457, USA.
Colon Ramos A; These authors contributed equally to this work.
Singh B; Department of Internal Medicine, St. Barnabas Hospital, Bronx, NY 10457, USA.
Sequeira Gross HG; These authors contributed equally to this work.
Gupta S; Department of Hematology/Oncology, Saint Joseph's University Medical Center, Paterson, NJ 07503, USA.

World J Oncol ; 12(4): 81-84, 2021 Aug.

Article en En | MEDLINE | ID: mdl-34349851

Palabras clave

Checkpoint inhibitors; Nivolumab; Pembrolizumab; Relapsed/refractory classical Hodgkin lymphoma

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: World J Oncol Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Canadá

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google